Term ends Sep 19, 2028 · High confidence
20-year base term ends May 21, 2028
Held by Arcturus Therapeutics, Inc.
Filed May 18, 2009 as application 12/515,403 · Granted Nov 20, 2012
Base term plus 121 days of patent term adjustment (USPTO delay)
Today
2008
2028
Clock starts
May 21, 2008
May 21, 2008
Term ends
Sep 19, 2028
Sep 19, 2028
Granted
Nov 20, 2012
Nov 20, 2012
base term
patent term adjustment
fee events
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
121
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 121 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 21, 2008, when application PCT/US2008/064417, the earliest non-provisional in its chain, was filed (this one was filed May 18, 2009) | May 21, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +121 days, USPTO patent term adjustment record | Sep 19, 2028 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Sep 19, 2028 | High confidence |
This family
| US 8,314,227 | this patent Sep 2028 | Sep 2028 |
| US 9,051,570 | In force Sep 2028 | Sep 2028 |
| US 9,303,260 | In force May 2028 | May 2028 |
| US 9,297,009 | In force May 2028 | May 2028 |
| US 9,944,929 | Lapsed on the fee record Apr 2026 | Apr 2026 |
| US 10,457,945 | In force May 2028 | May 2028 |
6 of 7 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 19, 2009 Reel 22704, frame 848 | Wengel, Jesper | Ribotask APS | Assignment of Assignor's Interest |
| May 19, 2009 Reel 22704, frame 988 | Ribotask APS | Mdrna, Inc. | Assignment of Assignor's Interest |
| Dec 29, 2009 Reel 23708, frame 389 | Mdrna, Inc.; Mdrna Research, Inc.; Nastech Pharmaceutical Company, Inc. | Eos Holdings LLC, as Agent | Security Agreement |
| Feb 23, 2010 Reel 23973, frame 286 | Eos Holdings LLC, as Agent | Mdrna, Inc.; Mdrna Research, Inc.; Nastech Pharmaceutical Company, Inc. | Release of Security Interest |
| Feb 23, 2010 reel/frame not recorded | Eos Holdings LLC, as Agent | Mdrna, Inc. | Release of Security Interest |
| Feb 23, 2010 reel/frame not recorded | Eos Holdings LLC, as Agent | Mdrna Research, Inc. | Release of Security Interest |
| Feb 23, 2010 reel/frame not recorded | Eos Holdings LLC, as Agent | Nastech Pharmaceutical Company, Inc. | Release of Security Interest |
| Apr 28, 2010 Reel 24300, frame 825 | Mdrna, Inc. FKA Nastech Pharmaceutical Company Inc. | Cequent Pharmaceuticals, Inc. | Security Agreement (PATENTS) |
| Jul 30, 2010 Reel 24767, frame 466 | Cequent Pharmaceuticals, Inc. | Marina Biotech, Inc. (F/K/A Mdrna, Inc.) | Release of Security Interest |
| Nov 20, 2010 Reel 25411, frame 379 | Mdrna, Inc. | Marina Biotech, Inc. | Change of Name |
| Feb 15, 2012 Reel 27712, frame 200 | Marina Biotech, Inc.; Cequent Pharmaceuticals, Inc.; Mdrna Research, Inc. | Genesis Capital Management, LLC, as Agent | Security Agreement |
| May 13, 2013 Reel 30401, frame 461 | Marina Biotech, Inc.; Cequent Pharmaceuticals, Inc.; Mdrna Research, Inc. | Monsanto Company | Security Agreement |
| Aug 19, 2013 Reel 31039, frame 193 | Marina Biotech, Inc. | Arcturus Therapeutics, Inc. | Assignment of Assignor's Interest |
| Apr 14, 2014 Reel 32685, frame 158 | Genesis Capital Management, LLC, as Agent | Marina Biotech, Inc.; Cequent Pharmaceuticals, Inc.; Mdrna Research, Inc. | Release of Security Interest |
| Apr 14, 2014 reel/frame not recorded | Genesis Capital Management, LLC, as Agent | Marina Biotech, Inc. | Release of Security Interest |
| Apr 14, 2014 reel/frame not recorded | Genesis Capital Management, LLC, as Agent | Cequent Pharmaceuticals, Inc. | Release of Security Interest |
| Apr 14, 2014 reel/frame not recorded | Genesis Capital Management, LLC, as Agent | Mdrna Research, Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Sep 2028
Term ends Sep 19, 2028. No further fees fall due before then
Note
The 121 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
51
later US patents cite this one
That is top 25% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.